Compare Vanguard Real Estate Index Fund ETF (VNQ) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Real Estate Index Fund ETF vs GeneDx Holdings Corp — how do they compare? Vanguard Real Estate Index Fund ETF trades at $90.65 (market cap $70.80B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Vanguard Real Estate Index Fund ETF is far larger — about 35× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is more actively traded (734,640 versus 6,073,580). Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Real Estate Index Fund ETF for 113 Days and GeneDx Holdings Corp for 19 Days on average.
| VNQ | WGS | |
|---|---|---|
Market Cap | $70.80B | $2.02B |
Volume | 6,073,580 | 734,640 |
52-Week High | $100.95 | $167.51 |
52-Week Low | $87.00 | $34.51 |
Typical Hold Time | 113 Days | 19 Days |
Sector | — | Health |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VNQ trades at $90.65, up 2.21% today, but faces bearish technical signals with 14 sell indicators versus 5 buys. The ETF has declined nearly 10% in the past month amid rising Treasury yields and Federal Reserve rate hikes, eroding its income appeal. Recent institutional buying by State Street Corp and Envestnet suggests some see value at current levels, while news highlights sector-wide REIT pressures and dividend yield comparisons with Treasury bills.
Outlook remains cautious with technical weakness and interest rate sensitivity posing near-term risks. However, contrarian investors may find opportunity in the sector sell-off if long-term real estate fundamentals hold. Key risks include further rate hikes and economic slowdowns affecting property valuations.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
